On September 2, 2026, the clinical trial registry listed an update for a study involving survodutide, also known as BI 456906. The trial, titled "A Study in People With Obesity to Test the Effects of BI 456906 Compared With Semaglutide on Glucagon Receptor Activity in the Liver," is registered under identifier NCT05202353.
This is a Phase 1 study conducted in people with obesity. According to the registry, the trial compares survodutide with semaglutide with respect to glucagon receptor activity in the liver.
The current status of the trial is listed as active, not recruiting. This means the study is ongoing but is no longer enrolling new participants at this time.
Survodutide remains classified as an unapproved compound under research investigation. No results have been reported in connection with this update, and no efficacy or safety conclusions can be drawn from a status change alone.
Readers interested in the background and mechanism of survodutide can consult the compound overview for additional context.